Early nuclear alterations and immunohistochemical expression of Ki-67, Erb-B2, vascular endothelial growth factor (VEGF), transforming growth factor (TGF-beta1) and integrine-linked kinase (ILK) two days after tamoxifen in breast carcinoma.
The purpose of the present study was to evaluate breast carcinoma samples before and two days after treatment with tamoxifen in order to analyse early histopathological alterations--particularlynuclear alterations-- as well as immunohistochemical expression of Ki-67, Erb-B2, VEGF, TGF-beta1 and ILK proteins. Twenty one cases of invasive ductal and lobular breast carcinoma were studied. Patients were submitted to biopsy of the lesion and, after confirmation of the diagnosis, they received 20 mg of tamoxifen a day, beginning two days before surgery. The samples obtained during biopsy and after surgery were stained with HE for histopathological diagnosis. Estrogen receptor was positive in 18 cases and negative in 3. The immunohistochemical method was applied for the detection of Ki-67, Erb-B2, protein, vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-beta1) and integrin linked kinase (ILK). Two days after tamoxifen treatment, the following results were observed: 1) decrease in the cell volume, chomatine condensation, nucleoli less evident and clearly defined nuclear limits; 2) significant reduction in the expression of Erb-B2 protein and significant increase in the expression of TGF-beta1 protein; 3) expression of others proteins (Ki-67, VEGF and ILK) was not altered during the indicated time frame. Our results suggest that analyzing nuclear alterations and expression of Erb-B2 and TGF-beta1 proteins would be useful to assess the initial response to tamoxifen.
Morena
A M L
AM
Radiotherapy Division of the Department of Medicine, Universidade Federal de Sao Paulo UNIFESP, Sao Paulo, Brazil. hrcs.dmed@epm.br
Oshima
C T F
CT
Gebrim
L H
LH
Egami
M I
MI
Silva
M R R
MR
Segreto
R A
RA
Giannotti Filho
O
O
Teixeira
V P C
VP
Segreto
H R C
HR
D001943:Breast Neoplasms / Q000378:metabolism* / Q000648:ultrastructure; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000378:metabolism; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000378:metabolism; D002467:Cell Nucleus / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D013629:Tamoxifen / Q000627:therapeutic use*; D016212:Transforming Growth Factor beta / Q000378:metabolism*; D053773:Transforming Growth Factor beta1; D042442:Vascular Endothelial Growth Factors / Q000378:metabolism*; D000099200:Scaffold Protein ILK
D019394:Ki-67 Antigen; D017346:Protein Serine-Threonine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D042442:Vascular Endothelial Growth Factors; D000099200:Scaffold Protein ILK; C508960:TGFB1 protein, human